Duration of Treatment for Gram-Negative Bacteremia Due to ESBL-Producing Organisms

Treatment Duration Recommendations

If the patient has persistent signs of infection after 4-7 days of therapy, further diagnostic investigation should be undertaken, including imaging to rule out undrained collections or persistent infectious foci 1

When treating ESBL-producing organisms, appropriate antibiotic selection is critical, with carbapenems generally considered the treatment of choice, according to the Infectious Diseases Society of America 2, 3
For ESBL-producing Enterobacteriaceae bacteremia, meropenem, imipenem-cilastatin, or ertapenem are appropriate options, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 2, 3
The choice of antimicrobial should be guided by susceptibility testing and local resistance patterns, as suggested by the World Society of Emergency Surgery 4

Persistent bacteremia despite appropriate antibiotic therapy may warrant extended treatment, according to the Infectious Diseases Society of America 1
Inadequate source control or difficult-to-achieve source control may also require extended treatment, as recommended by the Infectious Diseases Society of America 1
Deep-seated infections such as endovascular infections or osteomyelitis may necessitate extended treatment, according to the British Infection Association 5
Infections due to highly resistant pathogens with limited treatment options may require extended treatment, as suggested by the European Society of Clinical Microbiology and Infectious Diseases 2

Procalcitonin monitoring may be useful to guide antimicrobial discontinuation in complicated cases, according to the World Society of Emergency Surgery 6
For patients who do not respond to initial therapy, both extra-abdominal sources of infection and non-infectious inflammatory conditions should be investigated, as recommended by the Infectious Diseases Society of America 1

Failure to achieve adequate source control is a common reason for treatment failure and should be addressed before extending antibiotic duration, according to the World Society of Emergency Surgery 7

Deep-seated infections such as endovascular infections (e.g., endocarditis) require significantly longer therapy—up to 6 weeks as demonstrated in case reports of ESBL E. coli endocarditis 8
Standard dosing is meropenem 1-2 grams IV every 8 hours 9
Ertapenem 1 gram daily is an appropriate alternative for step-down therapy once clinical stability is achieved, particularly for non-severe infections 10

The World Health Organization recommends meropenem 1 gram IV every 8 hours as a 3-hour extended infusion for ESBL infections with normal renal function, with treatment duration of 4-7 days for intra-abdominal infections with adequate source control, or 10-14 days for bacteremia depending on source control and clinical response 11, 12
The Infectious Diseases Society of America recommends meropenem 1 gram IV every 8 hours for critically ill patients at risk for ESBL-producing Enterobacteriaceae 11, 12

The World Society of Emergency Surgery guidelines recommend treatment duration of 4-7 days after adequate source control in non-severely ill patients with intra-abdominal infections 11, 12
The World Society of Emergency Surgery guidelines demonstrate that fixed-duration therapy of approximately 4 days produces outcomes similar to extended courses (approximately 8 days) when source control is adequate 11, 12
The American College of Surgeons recommends maximum 10 days of treatment even without complete resolution of physiological abnormalities if source control achieved 11, 12

The European Society of Clinical Microbiology and Infectious Diseases recommends imipenem-cilastatin 1 gram every 8 hours or doripenem 500 mg every 8 hours as equivalent alternatives to meropenem 11, 12

The Infectious Diseases Society of America recommends considering ceftazidime-avibactam 2.5 grams IV every 8 hours or ceftolozane-tazobactam for non-severe infections or after clinical stability achieved, guided by susceptibility testing 13